Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board

RECURSION PHARMACEUTICALS, INC.

Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.
Dr. Bumpus served as FDA Principal Deputy Commissioner until Dec 2024, brings regulatory and AI-in-science expertise.
Elaine Sun is COO/CFO of Mammoth Biosciences, ex-CFO of Halozyme, with 30 years life sciences finance experience.
New committees: R&D and Technology; Sun chairs Audit, Bumpus joins Nominating, R&D, and Technology committees.
Director compensation policy amended to cover new committee roles.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elaine Sun

Director

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2025-03-15
Filed: March 18, 2025, 7:59 PM ET

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

Appointed

Dr. Namandjé Bumpus

Director

RXRX · RECURSION PHARMACEUTICALS, INC.

Effective: 2025-03-15
Filed: March 18, 2025, 7:59 PM ET

The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.

View on SEC.gov

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001601830-25-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.